2,073
Trials as lead sponsor
Most active programmes
The drugs appearing most often across AbbVie's recently active trials. Comparator arms are excluded.
- Risankizumab9 trials
- Atogepant8 trials
- Telisotuzumab Adizutecan7 trials
- Carboplatin6 trials
- Bevacizumab6 trials
- Upadacitinib5 trials
Upcoming readouts
Next primary completion dates among AbbVie's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Aug 2026Switch-Up: A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inad…Phase 3
- Sept 2026A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the…Phase 3
- Nov 2026Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Ant…Phase 2
- Feb 2027A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisPhase 2
- Mar 20273112 Ped BPD: A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Tr…Phase 3
- Apr 2027Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episod…Phase 2
Top therapeutic areas
Conditions studied most often across AbbVie's recently active trials.
- Migraine8 trials
- Ulcerative Colitis5 trials
- Crohn's Disease4 trials
- Multiple Myeloma4 trials
- Chronic Migraine3 trials
- Non-Small Cell Lung Cancer3 trials
AbbVie trials
The 50 most significant of AbbVie's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| Switch-UpA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabNCT06389136Upadacitinib 15mg Dose | Phase 3 | Locked · track to reveal | OngoingRecruiting | 200 est. | Aug 2026 |
| ATO MMStudy of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineNCT06806293Atogepant | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 468 est. | Aug 2026 |
| A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye DiseaseNCT07284381ABBV-444 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 261 est. | Aug 2026 |
| A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabNCT06100744Adalimumab | Phase 3 | Locked · track to reveal | OngoingRecruiting | 40 est. | Sept 2026 |
| A Study to Assess the Adverse Events and How Bretisilocin Intramuscular Injection Moves Through the Body of Healthy Adult ParticipantsNCT07604558Bretisilocin | Phase 1 | Locked · track to reveal | OngoingRecruiting | 26 est. | Sept 2026 |
| A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male ParticipantsNCT06953934ABBV-932 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 8 est. | Sept 2026 |
| A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult ParticipantsNCT07649954Nacresertib | Phase 1 | Not yet scored | OngoingNot yet recruiting | 12 est. | Sept 2026 |
| Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult ParticipantsNCT07680686Ubrogepant | Phase 1 | Not yet scored | OngoingNot yet recruiting | 52 est. | Oct 2026 |
| Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety DisorderNCT06846320ABBV-932 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 315 est. | Nov 2026 |
| IntrepidA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis SuppurativaNCT06468228Lutikizumab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 1,400 est. | Dec 2026 |
| A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult ParticipantsNCT07466550Risankizumab | Phase 1 | Locked · track to reveal | OngoingRecruiting | 60 est. | Jan 2027 |
| ONIROSA Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/FoscarbidopaNCT07284342 | — | Not yet scored | OngoingRecruiting | 103 est. | Jan 2027 |
| A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisNCT06972446Lutikizumab | Phase 2 | Locked · track to reveal | OngoingRecruiting | 180 est. | Feb 2027 |
| 3112 Ped BPDA Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.NCT04777357Cariprazine | Phase 3 | Locked · track to reveal | OngoingRecruiting | 380 est. | Mar 2027 |
| Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II DisorderNCT07220460ABBV-932 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 200 est. | Apr 2027 |
| Ubro PedsStudy to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)NCT05125302Ubrogepant | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,059 est. | May 2027 |
| A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate CancerNCT06318273ABBV-969 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 152 est. | May 2027 |
| U-EMPOWERCrohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's DiseaseNCT06332534Upadacitinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 110 est. | Jun 2027 |
| UBRO MMStudy of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual MigraineNCT06417775Ubrogepant | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 496 est. | Jun 2027 |
| Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanNCT05005403Azirkitug | Phase 1 | Locked · track to reveal | OngoingRecruiting | 694 est. | Jul 2027 |
| ELARIS EM-COCStudy Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe PainNCT04333576Elagolix | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 800 est. | Jul 2027 |
| A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 InjectionsNCT07232004ABBV-547 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 121 est. | Aug 2027 |
| EUROPEStudy of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative ColitisNCT05496348 | — | Locked · track to reveal | OngoingActive, not recruiting | 400 est. | Aug 2027 |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive DisorderNCT07276997Icalcaprant | Phase 2 | Locked · track to reveal | OngoingRecruiting | 195 est. | Sept 2027 |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II DisorderNCT06696755Icalcaprant | Phase 2 | Locked · track to reveal | OngoingRecruiting | 195 est. | Nov 2027 |
| Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623Telisotuzumab Adizutecan | Phase 1 | Locked · track to reveal | OngoingRecruiting | 252 est. | Nov 2027 |
| CERVINOStudy Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaNCT06158841Etentamig | Phase 3 | Locked · track to reveal | OngoingRecruiting | 380 est. | Dec 2027 |
| CROHNOSA Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World SettingNCT07073079 | — | Locked · track to reveal | OngoingRecruiting | 250 est. | Dec 2027 |
| A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT06568939Telisotuzumab Vedotin | Phase 2 | Locked · track to reveal | OngoingRecruiting | 150 est. | Feb 2028 |
| A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult ParticipantsNCT07673120ABBV-313 | Phase 1 | Not yet scored | OngoingRecruiting | 64 est. | Feb 2028 |
| Step-Up HSA Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyNCT05889182Upadacitinib | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,328 est. | Mar 2028 |
| A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic MigraineNCT05711394Atogepant | Phase 3 | Locked · track to reveal | OngoingRecruiting | 450 est. | Mar 2028 |
| AndroMETa-CRCA Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal CancerNCT06820463Telisotuzumab Adizutecan | Phase 2 | Locked · track to reveal | OngoingRecruiting | 390 est. | Mar 2028 |
| DREAMStudy to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque PsoriasisNCT07039110 | — | Locked · track to reveal | OngoingRecruiting | 700 est. | Mar 2028 |
| Viti-UpA Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With VitiligoNCT06118411Upadacitinib | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 614 est. | Mar 2028 |
| PRACTICEStudy to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United KingdomNCT07690215 | — | Locked · track to reveal | OngoingNot yet recruiting | 200 est. | Mar 2028 |
| A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)NCT07306832Pivekimab Sunirine | Phase 1 | Locked · track to reveal | OngoingRecruiting | 18 est. | Apr 2028 |
| NAAVIGATESurabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular EdemaNCT07592273Surabgene Lomparvovec | Phase 2 | Locked · track to reveal | OngoingRecruiting | 576 est. | Jun 2028 |
| Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative ColitisNCT06764706 | — | Locked · track to reveal | OngoingRecruiting | 200 est. | Jul 2028 |
| Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia RepairNCT07226791AGN-151607-DP | Phase 2 | Locked · track to reveal | OngoingRecruiting | 200 est. | Sept 2028 |
| ProParkBA Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in BelgiumNCT07382440 | — | Not yet scored | OngoingRecruiting | 120 est. | Sept 2028 |
| A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With GlaucomaNCT06822738XEN63 Glaucoma Treatment System | Phase 3 | Locked · track to reveal | OngoingRecruiting | 130 est. | Nov 2028 |
| Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential TremorNCT07673107AGN-151607-DP | Phase 2 | Not yet scored | OngoingRecruiting | 94 est. | Nov 2028 |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)NCT04928846Telisotuzumab Vedotin | Phase 3 | Locked · track to reveal | OngoingRecruiting | 768 est. | Dec 2028 |
| FLORENZAA Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian CancerNCT07059845Mirvetuximab Soravtansine | Phase 2 | Locked · track to reveal | OngoingRecruiting | 400 est. | Jan 2029 |
| A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian CancerNCT07278336ABBV-901 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 219 est. | Jan 2029 |
| A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)NCT07607964ABBV-519 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 30 est. | Jan 2029 |
| SEZanneA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung CancerNCT07155174ABBV-706 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 180 est. | Apr 2029 |
| AndroMETa-CRCA Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal CancerNCT07525206Telisotuzumab adizutecan | Phase 3 | Locked · track to reveal | OngoingRecruiting | 700 est. | May 2029 |
| Atogepant PMSSPost-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic MigraineNCT06603558Atogepant | — | Locked · track to reveal | OngoingRecruiting | 3,000 est. | May 2029 |